{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:53:32Z","timestamp":1794671612322,"version":"4.9.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inherited hematologic disorders such as sickle cell disease (SCD), thalassemia, and hemophilia are rare but devastating conditions with high morbidity and mortality. Advances in gene therapy have opened curative prospects. The objective of the current study was to provide a comprehensive bibliometric and knowledge-mapping analysis of global research on gene therapy targeting SCD, thalassemia, and hemophilia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Scopus-based bibliometric search was conducted for the period from 1986 to 2024. The search used title-specific queries for the target diseases and title-abstract queries for gene therapy technologies. Bibliometric indicators and network visualization maps, created by VOSviewer, were presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 1399 articles were retrieved. Publication growth revealed two phases: a steady, but slow phase (1986\u20132018), and mature expansion phase (2019\u20132024), with an average annual growth rate of 28% over the last decade. The articles had a mean of 47.6 citations\/article and an H-index of 126. Research was mainly distributed across medicine (39.5%), biochemistry\/genetics\/molecular biology (30.7%), immunology (8.1%), and pharmacology\/toxicology (7.5%), reflecting the multidisciplinary nature of the field. The most prolific journal was\n                      <jats:italic>Blood<\/jats:italic>\n                      (8.6%), followed by\n                      <jats:italic>Hemophilia<\/jats:italic>\n                      ,\n                      <jats:italic>Molecular Therapy<\/jats:italic>\n                      ,\n                      <jats:italic>Human Gene Therapy<\/jats:italic>\n                      , and\n                      <jats:italic>Blood Advances<\/jats:italic>\n                      . The United Stated dominated the field (n\u2009=\u2009863; 61.7%), followed by China and the United Kingdom, with the United States showing strong intra-country collaborations, while European countries demonstrated high international collaborations, often with the United States. Leading institutions included the Children\u2019s Hospital of Philadelphia (7.5%) and University of Pennsylvania (5.9%). Co-authorship analysis revealed robust collaboration networks, with notable clusters around AAV-based hemophilia therapy and CRISPR-mediated gene correction for hemoglobinopathies. Keyword co-occurrence highlighted themes like AAV vectors, genome editing, CRISPR-Case9, and ex vivo hematopoietic stem cell modification. Overlay visualization maps indicated a recent surge in CRISPR and clinical applications research.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The bibliometric findings underscore the rapid evolution of gene therapy research for SCD, thalassemia, and hemophilia, moving from experimental approaches to clinical translation. The strong interdisciplinary collaboration, rising clinical trials, and emergence of genome editing tools suggest that the field is entering a transformative era, offering real-world therapeutic solutions for previously incurable inherited blood disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03957-0","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T11:17:44Z","timestamp":1762255064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Knowledge mapping and bibliometric insights into gene therapy for rare inherited hematologic pathologies: focus on sickle cell disease, hemophilia, and thalassemia"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7130-156X","authenticated-orcid":false,"given":"Moutaz W.","family":"Sweileh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"3957_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/978-3-031-44080-9_80","volume-title":"The EBMT handbook: hematopoietic cell transplantation and cellular therapies","author":"B Cappelli","year":"2024","unstructured":"Cappelli B, Gluckman E, Corbacioglu S, de la Fuente J, Abboud MR. Hemoglobinopathies (Sickle Cell Disease and Thalassemia). In: Sureda A, Corbacioglu S, Greco R, Kr\u00f6ger N, Carreras E, editors. The EBMT handbook: hematopoietic cell transplantation and cellular therapies. Cham: Springer; 2024. p. 725\u201339."},{"key":"3957_CR2","first-page":"221","volume":"15","author":"E Marchesini","year":"2021","unstructured":"Marchesini E, Morfini M, Valentino L. Recent advances in the treatment of hemophilia: a review. Biologics. 2021;15:221\u201335.","journal-title":"Biologics"},{"key":"3957_CR3","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1097\/01.HS9.0000851688.00394.f4","volume":"6","author":"R Colombatti","year":"2022","unstructured":"Colombatti R, Birkeg\u00e5rd C, Medici M. PB2215: global epidemiology of sickle cell disease: a systematic literature review. HemaSphere. 2022;6:2085\u20136.","journal-title":"HemaSphere"},{"issue":"4","key":"3957_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/thalassrep14040010","volume":"14","author":"IZ Sadiq","year":"2024","unstructured":"Sadiq IZ, Abubakar FS, Usman HS, Abdullahi AD, Ibrahim B, Kastayal BS, et al. Thalassemia: pathophysiology, diagnosis, and advances in treatment. Thalassemia Rep. 2024;14(4):81\u2013102.","journal-title":"Thalassemia Rep"},{"key":"3957_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-93990-8","volume-title":"Advances in Hemophilia treatment : from genetics to joint health","author":"EC Rodr\u00edguez-Merch\u00e1n","year":"2022","unstructured":"Rodr\u00edguez-Merch\u00e1n EC, Jim\u00e9nez-Yuste V. Pathophysiology of hemophilia. In: Rodr\u00edguez-Merch\u00e1n EC, editor. Advances in Hemophilia treatment\u202f: from genetics to joint health. Cham: Springer; 2022. p. 1\u20139."},{"key":"3957_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120375","volume":"294","author":"N Sayed","year":"2022","unstructured":"Sayed N, Allawadhi P, Khurana A, Singh V, Navik U, Pasumarthi SK, et al. Gene therapy: comprehensive overview and therapeutic applications. Life Sci. 2022;294: 120375.","journal-title":"Life Sci"},{"issue":"2","key":"3957_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijns5020020","volume":"5","author":"BPD Inusa","year":"2019","unstructured":"Inusa BPD, Hsu LL, Kohli N, Patel A, Ominu-Evbota K, Anie KA, et al. Sickle cell disease\u2014genetics, pathophysiology, clinical presentation and treatment. Int J Neonatal Screen. 2019;5(2): 20.","journal-title":"Int J Neonatal Screen"},{"key":"3957_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.10.012","volume":"39","author":"X Shang","year":"2017","unstructured":"Shang X, Xu X. Update in the genetics of thalassemia: what clinicians need to know. Best Pract Res Clin Obstet Gynaecol. 2017;39:3\u201315.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"5","key":"3957_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052762","volume":"23","author":"G Shen","year":"2022","unstructured":"Shen G, Gao M, Cao Q, Li W. The molecular basis of FIX deficiency in hemophilia B. Int J Mol Sci. 2022;23(5): 2762.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3957_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/ph15060753","volume":"15","author":"R Bou-Fakhredin","year":"2022","unstructured":"Bou-Fakhredin R, De Franceschi L, Motta I, Cappellini MD, Taher AT. Pharmacological induction of fetal hemoglobin in \u03b2-thalassemia and sickle cell disease: an updated perspective. Pharmaceuticals. 2022;15(6):753.","journal-title":"Pharmaceuticals"},{"issue":"7","key":"3957_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jcyt.2024.11.006","volume":"27","author":"J Ballantine","year":"2024","unstructured":"Ballantine J, Tisdale JF. Gene therapy for sickle cell disease: recent advances, clinical trials and future directions. Cytotherapy. 2024;27(7):826\u201334.","journal-title":"Cytotherapy"},{"issue":"8","key":"3957_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706\u201318.","journal-title":"N Engl J Med"},{"issue":"11","key":"3957_CR13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt AD, Laffan M, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013\u201325.","journal-title":"N Engl J Med"},{"issue":"51\u201352","key":"3957_CR14","first-page":"878","volume":"117","author":"J Kirschner","year":"2020","unstructured":"Kirschner J, Cathomen T. Gene therapy for monogenic inherited disorders. Dtsch Arztebl Int. 2020;117(51\u201352):878\u201385.","journal-title":"Dtsch Arztebl Int"},{"issue":"7\u20138","key":"3957_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/s41434-019-0093-4","volume":"26","author":"AM Al-Saif","year":"2019","unstructured":"Al-Saif AM. Gene therapy of hematological disorders: current challenges. Gene Ther. 2019;26(7\u20138):296\u2013307.","journal-title":"Gene Ther"},{"issue":"2","key":"3957_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.hoc.2022.12.012","volume":"37","author":"GE Christakopoulos","year":"2023","unstructured":"Christakopoulos GE, Telange R, Yen J, Weiss MJ. Gene therapy and gene editing for \u03b2-thalassemia. Hematol Oncol Clin North Am. 2023;37(2):433\u201347.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"3","key":"3957_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul H, Altshuler D, Cappellini MD, Chen YS, Domm J, Eustace BK, et al. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384(3):252\u201360.","journal-title":"N Engl J Med"},{"issue":"8","key":"3957_CR18","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","volume":"28","author":"B Fu","year":"2022","unstructured":"Fu B, Liao J, Chen S, Li W, Wang Q, Hu J, et al. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b2(0)\/\u03b2(0) transfusion-dependent \u03b2-thalassemia. Nat Med. 2022;28(8):1573\u201380.","journal-title":"Nat Med"},{"key":"3957_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147480","volume":"874","author":"L Ma","year":"2023","unstructured":"Ma L, Yang S, Peng Q, Zhang J, Zhang J. CRISPR\/Cas9-based gene-editing technology for sickle cell disease. Gene. 2023;874: 147480.","journal-title":"Gene"},{"issue":"1","key":"3957_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2021.103060","volume":"60","author":"SH Park","year":"2021","unstructured":"Park SH, Bao G. CRISPR\/Cas9 gene editing for curing sickle cell disease. Transfus Apher Sci. 2021;60(1): 103060.","journal-title":"Transfus Apher Sci"},{"key":"3957_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.116636","volume":"232","author":"D Gupta","year":"2019","unstructured":"Gupta D, Bhattacharjee O, Mandal D, Sen MK, Dey D, Dasgupta A, et al. CRISPR-Cas9 system: a new-fangled dawn in gene editing. Life Sci. 2019;232: 116636.","journal-title":"Life Sci"},{"issue":"10","key":"3957_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.52586\/4997","volume":"26","author":"S Huang","year":"2021","unstructured":"Huang S, Yan Y, Su F, Huang X, Xia D, Jiang X, et al. Research progress in gene editing technology. Front Biosci (Landmark Ed). 2021;26(10):916\u201327.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"3957_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249604","author":"E Janik","year":"2020","unstructured":"Janik E, Niemcewicz M, Ceremuga M, Krzowski L, Saluk-Bijak J, Bijak M. Various aspects of a gene editing system-CRISPR-Cas9. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21249604.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3957_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/j.semperi.2018.09.003","volume":"42","author":"F Memi","year":"2018","unstructured":"Memi F, Ntokou A, Papangeli I. CRISPR\/Cas9 gene-editing: research technologies, clinical applications and ethical considerations. Semin Perinatol. 2018;42(8):487\u2013500.","journal-title":"Semin Perinatol"},{"issue":"4","key":"3957_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1534\/genetics.111.131433","volume":"188","author":"D Carroll","year":"2011","unstructured":"Carroll D. Genome engineering with zinc-finger nucleases. Genetics. 2011;188(4):773\u201382.","journal-title":"Genetics"},{"key":"3957_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/bs.pmbts.2017.04.006","volume":"149","author":"H Bi","year":"2017","unstructured":"Bi H, Yang B. Gene editing with TALEN and CRISPR\/Cas in rice. Prog Mol Biol Transl Sci. 2017;149:81\u201398.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5","key":"3957_CR27","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1161\/CIRCRESAHA.116.309727","volume":"120","author":"T Doetschman","year":"2017","unstructured":"Doetschman T, Georgieva T. Gene editing with CRISPR\/Cas9 RNA-directed nuclease. Circ Res. 2017;120(5):876\u201394.","journal-title":"Circ Res"},{"issue":"4","key":"3957_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1631\/jzus.B2100009","volume":"22","author":"C Li","year":"2021","unstructured":"Li C, Brant E, Budak H, Zhang B. CRISPR\/Cas: a Nobel Prize award-winning precise genome editing technology for gene therapy and crop improvement. J Zhejiang Univ Sci B. 2021;22(4):253\u201384.","journal-title":"J Zhejiang Univ Sci B"},{"issue":"6629","key":"3957_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/science.add8643","volume":"379","author":"JY Wang","year":"2023","unstructured":"Wang JY, Doudna JA. Crispr technology: a decade of genome editing is only the beginning. Science. 2023;379(6629): eadd8643.","journal-title":"Science"},{"key":"3957_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbusres.2021.04.070","volume":"133","author":"N Donthu","year":"2021","unstructured":"Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: an overview and guidelines. J Bus Res. 2021;133:285\u201396.","journal-title":"J Bus Res"},{"issue":"2","key":"3957_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","volume":"26","author":"MJ Grant","year":"2009","unstructured":"Grant MJ, Booth A. A typology of reviews: an analysis of 14 review types and associated methodologies. Health Inf Libr J. 2009;26(2):91\u2013108.","journal-title":"Health Inf Libr J"},{"issue":"3","key":"3957_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/hir.12276","volume":"36","author":"A Sutton","year":"2019","unstructured":"Sutton A, Clowes M, Preston L, Booth A. Meeting the review family: exploring review types and associated information retrieval requirements. Health Inf Libr J. 2019;36(3):202\u201322.","journal-title":"Health Inf Libr J"},{"issue":"1","key":"3957_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13643-023-02410-2","volume":"12","author":"A Montazeri","year":"2023","unstructured":"Montazeri A, Mohammadi S, Hesari PM, Ghaemi M, Riazi H, Sheikhi-Mobarakeh Z. Preliminary guideline for reporting bibliometric reviews of the biomedical literature (BIBLIO): a minimum requirements. Syst Rev. 2023;12(1):239.","journal-title":"Syst Rev"},{"issue":"46","key":"3957_CR34","doi-asserted-by":"publisher","first-page":"16569","DOI":"10.1073\/pnas.0507655102","volume":"102","author":"JE Hirsch","year":"2005","unstructured":"Hirsch JE. An index to quantify an individual\u2019s scientific research output. Proc Natl Acad Sci U S A. 2005;102(46):16569\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3957_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2023.102339","volume":"11","author":"UA Bukar","year":"2023","unstructured":"Bukar UA, Sayeed MS, Razak SFA, Yogarayan S, Amodu OA, Mahmood RAR. A method for analyzing text using VOSviewer. MethodsX. 2023;11: 102339.","journal-title":"MethodsX"},{"issue":"3","key":"3957_CR36","doi-asserted-by":"publisher","first-page":"392","DOI":"10.5195\/jmla.2022.1434","volume":"110","author":"H Arruda","year":"2022","unstructured":"Arruda H, Silva ER, Lessa M, Proen\u00e7a D Jr, Bartholo R. VOSviewer and Bibliometrix. J Med Libr Assoc. 2022;110(3):392\u20135.","journal-title":"J Med Libr Assoc"},{"issue":"3","key":"3957_CR37","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/nm1358","volume":"12","author":"CS Manno","year":"2006","unstructured":"Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342\u20137.","journal-title":"Nat Med"},{"issue":"25","key":"3957_CR38","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","volume":"365","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365(25):2357\u201365.","journal-title":"N Engl J Med"},{"issue":"21","key":"3957_CR39","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","volume":"371","author":"AC Nathwani","year":"2014","unstructured":"Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014;371(21):1994\u20132004.","journal-title":"N Engl J Med"},{"issue":"3","key":"3957_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/73464","volume":"24","author":"MA Kay","year":"2000","unstructured":"Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24(3):257\u201361.","journal-title":"Nat Genet"},{"issue":"8","key":"3957_CR41","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","volume":"101","author":"CS Manno","year":"2003","unstructured":"Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101(8):2963\u201372.","journal-title":"Blood"},{"issue":"23","key":"3957_CR42","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215\u201327.","journal-title":"N Engl J Med"},{"issue":"26","key":"3957_CR43","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519\u201330.","journal-title":"N Engl J Med"},{"issue":"7313","key":"3957_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","volume":"467","author":"M Cavazzana-Calvo","year":"2010","unstructured":"Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia. Nature. 2010;467(7313):318\u201322.","journal-title":"Nature"},{"issue":"7629","key":"3957_CR45","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","volume":"539","author":"DP Dever","year":"2016","unstructured":"Dever DP, Bak RO, Reinisch A, Camarena J, Washington G, Nicolas CE, et al. CRISPR\/Cas9 \u03b2-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539(7629):384\u20139.","journal-title":"Nature"},{"issue":"13","key":"3957_CR46","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","volume":"119","author":"G Buchlis","year":"2012","unstructured":"Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood. 2012;119(13):3038\u201341.","journal-title":"Blood"},{"key":"3957_CR47","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1749-6632.2001.tb11361.x","volume":"953","author":"KA High","year":"2001","unstructured":"High KA. AAV-mediated gene transfer for hemophilia. Ann N Y Acad Sci. 2001;953:64\u201374.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"3957_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101205","volume":"32","author":"BS Doshi","year":"2024","unstructured":"Doshi BS, Samelson-Jones BJ, Nichols TC, Merricks EP, Siner JL, French RA, et al. AAV gene therapy in companion dogs with severe hemophilia: real-world long-term data on immunogenicity, efficacy, and quality of life. Mol Ther Methods Clin Dev. 2024;32(1): 101205.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"3957_CR49","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1089\/104303402760128513","volume":"13","author":"RW Herzog","year":"2002","unstructured":"Herzog RW, Fields PA, Arruda VR, Brubaker JO, Armstrong E, McClintock D, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002;13(11):1281\u201391.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"3957_CR50","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2011-01-332510","volume":"118","author":"MM Hsieh","year":"2011","unstructured":"Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118(5):1197\u2013207.","journal-title":"Blood"},{"issue":"24","key":"3957_CR51","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","volume":"361","author":"MM Hsieh","year":"2009","unstructured":"Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309\u201317.","journal-title":"N Engl J Med"},{"key":"3957_CR52","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1146\/annurev.biochem.74.050304.091637","volume":"74","author":"IM Verma","year":"2005","unstructured":"Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annu Rev Biochem. 2005;74:711\u201338.","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"3957_CR53","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.ymthe.2006.03.001","volume":"13","author":"AW Nienhuis","year":"2006","unstructured":"Nienhuis AW, Dunbar CE, Sorrentino BP. Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther. 2006;13(6):1031\u201349.","journal-title":"Mol Ther"},{"issue":"5644","key":"3957_CR54","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1126\/science.1088547","volume":"302","author":"S Hacein-Bey-Abina","year":"2003","unstructured":"Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415\u20139.","journal-title":"Science"},{"key":"3957_CR55","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.682","author":"A Aiuti","year":"2009","unstructured":"Aiuti A, Roncarolo MG. Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program. 2009. https:\/\/doi.org\/10.1182\/asheducation-2009.1.682.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"3957_CR56","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/cge.12576","volume":"88","author":"A Fischer","year":"2015","unstructured":"Fischer A, Hacein-Bey Abina S, Touzot F, Cavazzana M. Gene therapy for primary immunodeficiencies. Clin Genet. 2015;88(6):507\u201315.","journal-title":"Clin Genet"},{"issue":"5","key":"3957_CR57","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ymthe.2017.03.024","volume":"25","author":"M Cavazzana","year":"2017","unstructured":"Cavazzana M, Antoniani C, Miccio A. Gene Therapy for \u03b2-Hemoglobinopathies. Mol Ther. 2017;25(5):1142\u201354.","journal-title":"Mol Ther"},{"issue":"5","key":"3957_CR58","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","volume":"25","author":"AW Nienhuis","year":"2017","unstructured":"Nienhuis AW, Nathwani AC, Davidoff AM. Gene therapy for hemophilia. Mol Ther. 2017;25(5):1163\u20137.","journal-title":"Mol Ther"},{"key":"3957_CR59","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1146\/annurev-med-012017-043332","volume":"70","author":"XM Anguela","year":"2019","unstructured":"Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273\u201388.","journal-title":"Annu Rev Med"},{"issue":"6","key":"3957_CR60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/MOH.0000000000000385","volume":"24","author":"DP Dever","year":"2017","unstructured":"Dever DP, Porteus MH. The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation. Curr Opin Hematol. 2017;24(6):481\u20138.","journal-title":"Curr Opin Hematol"},{"key":"3957_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111843","author":"P Germino-Watnick","year":"2022","unstructured":"Germino-Watnick P, Hinds M, Le A, Chu R, Liu X, Uchida N. Hematopoietic stem cell gene-addition\/editing therapy in sickle cell disease. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11111843.","journal-title":"Cells"},{"issue":"4","key":"3957_CR62","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.hoc.2022.03.008","volume":"36","author":"A Leonard","year":"2022","unstructured":"Leonard A, Tisdale JF, Bonner M. Gene therapy for hemoglobinopathies: beta-thalassemia, sickle cell disease. Hematol Oncol Clin North Am. 2022;36(4):769\u201395.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"3957_CR63","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1007\/s11427-021-1952-5","volume":"64","author":"X Wang","year":"2021","unstructured":"Wang X, Ma C, Rodr\u00edguez Labrada R, Qin Z, Xu T, He Z, et al. Recent advances in lentiviral vectors for gene therapy. Sci China Life Sci. 2021;64(11):1842\u201357.","journal-title":"Sci China Life Sci"},{"issue":"9","key":"3957_CR64","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1056\/NEJMoa1609677","volume":"376","author":"JA Ribeil","year":"2017","unstructured":"Ribeil JA, Hacein-Bey-Abina S, Payen E, Magnani A, Semeraro M, Magrin E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9):848\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"3957_CR65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","volume":"122","author":"F Mingozzi","year":"2013","unstructured":"Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood. 2013;122(1):23\u201336.","journal-title":"Blood"},{"issue":"1","key":"3957_CR66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12185-018-2513-4","volume":"111","author":"T Ohmori","year":"2020","unstructured":"Ohmori T. Advances in gene therapy for hemophilia: basis, current status, and future perspectives. Int J Hematol. 2020;111(1):31\u201341.","journal-title":"Int J Hematol"},{"key":"3957_CR67","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fimmu.2020.00494","volume":"11","author":"SR Patel","year":"2020","unstructured":"Patel SR, Lundgren TS, Spencer HT, Doering CB. The immune response to the fVIII gene therapy in preclinical models. Front Immunol. 2020;11:494.","journal-title":"Front Immunol"},{"issue":"2","key":"3957_CR68","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nprot.2017.143","volume":"13","author":"RO Bak","year":"2018","unstructured":"Bak RO, Dever DP, Porteus MH. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc. 2018;13(2):358\u201376.","journal-title":"Nat Protoc"},{"key":"3957_CR69","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/bs.pmbts.2021.01.025","volume":"182","author":"M Brusson","year":"2021","unstructured":"Brusson M, Miccio A. Genome editing approaches to \u03b2-hemoglobinopathies. Prog Mol Biol Transl Sci. 2021;182:153\u201383.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"3957_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100800","author":"M Laurent","year":"2024","unstructured":"Laurent M, Geoffroy M, Pavani G, Guiraud S. CRISPR-based gene therapies: from preclinical to clinical treatments. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13100800.","journal-title":"Cells"},{"issue":"23","key":"3957_CR71","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe1312702","volume":"384","author":"J Mehta","year":"2021","unstructured":"Mehta J. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384(23): e91.","journal-title":"N Engl J Med"},{"issue":"23","key":"3957_CR72","volume":"384","author":"R Meisel","year":"2021","unstructured":"Meisel R. CRISPR-Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N Engl J Med. 2021;384(23): e91.","journal-title":"N Engl J Med"},{"key":"3957_CR73","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944204","volume":"30","author":"DV Parums","year":"2024","unstructured":"Parums DV. Editorial: First regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia. Med Sci Monit. 2024;30: e944204.","journal-title":"Med Sci Monit"},{"issue":"5","key":"3957_CR74","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","volume":"25","author":"Y Wu","year":"2019","unstructured":"Wu Y, Zeng J, Roscoe BP, Liu P, Yao Q, Lazzarotto CR, et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat Med. 2019;25(5):776\u201383.","journal-title":"Nat Med"},{"issue":"4","key":"3957_CR75","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13312-023-2865-1","volume":"60","author":"Y Arya","year":"2023","unstructured":"Arya Y, Sahi PK. Cell-Based Gene Therapy for b-Thalassemia. Indian Pediatr. 2023;60(4):313\u20136.","journal-title":"Indian Pediatr"},{"issue":"5","key":"3957_CR76","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","volume":"386","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Thompson AA, Kwiatkowski JL, Porter JB, Thrasher AJ, Hongeng S, et al. Betibeglogene autotemcel gene therapy for non-\u03b2(0)\/\u03b2(0) genotype \u03b2-thalassemia. N Engl J Med. 2022;386(5):415\u201327.","journal-title":"N Engl J Med"},{"issue":"1","key":"3957_CR77","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1182\/hematology.2022000388","volume":"2022","author":"AC Nathwani","year":"2022","unstructured":"Nathwani AC. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2022;2022(1):569\u201378.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"12","key":"3957_CR78","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1080\/14712598.2023.2282138","volume":"23","author":"T Sekayan","year":"2023","unstructured":"Sekayan T, Simmons DH, von Drygalski A. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). Expert Opin Biol Ther. 2023;23(12):1173\u201384.","journal-title":"Expert Opin Biol Ther"},{"key":"3957_CR79","volume":"2","author":"CD Thornburg","year":"2021","unstructured":"Thornburg CD. Etranacogene dezaparvovec for hemophilia B gene therapy. Ther Adv Rare Dis. 2021;2: 26330040211058896.","journal-title":"Ther Adv Rare Dis"},{"issue":"Suppl 1","key":"3957_CR80","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/ijlh.13605","volume":"43","author":"P Batty","year":"2021","unstructured":"Batty P, Lillicrap D. Gene therapy for hemophilia: current status and laboratory consequences. Int J Lab Hematol. 2021;43(Suppl 1):117\u201323.","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"3957_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101619","volume":"5","author":"F Esposito","year":"2024","unstructured":"Esposito F, Dell\u2019Aquila F, Rhiel M, Auricchio S, Chmielewski KO, Andrieux G, et al. Safe and effective liver-directed AAV-mediated homology-independent targeted integration in mouse models of inherited diseases. Cell Rep Med. 2024;5(7): 101619.","journal-title":"Cell Rep Med"},{"key":"3957_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101185","volume":"65","author":"M Dimitrievska","year":"2024","unstructured":"Dimitrievska M, Bansal D, Vitale M, Strouboulis J, Miccio A, Nicolaides KH, et al. Revolutionising healing: gene editing\u2019s breakthrough against sickle cell disease. Blood Rev. 2024;65: 101185.","journal-title":"Blood Rev"},{"issue":"2","key":"3957_CR83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40291-019-00386-1","volume":"23","author":"E Katsantoni","year":"2019","unstructured":"Katsantoni E. Omics studies in hemoglobinopathies. Mol Diagn Ther. 2019;23(2):223\u201334.","journal-title":"Mol Diagn Ther"},{"key":"3957_CR84","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-genom-120122-081037","volume":"24","author":"G Hardouin","year":"2023","unstructured":"Hardouin G, Magrin E, Corsia A, Cavazzana M, Miccio A, Semeraro M. Sickle cell disease: from genetics to curative approaches. Annu Rev Genomics Hum Genet. 2023;24:255\u201375.","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"5","key":"3957_CR85","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.ymthe.2024.03.005","volume":"32","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Cavazzana M, Frangoul H, Fuente J, Algeri M, Meisel R. Autologous gene therapy for hemoglobinopathies: from bench to patient\u2019s bedside. Mol Ther. 2024;32(5):1202\u201318.","journal-title":"Mol Ther"},{"issue":"7","key":"3957_CR86","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41375-018-0106-0","volume":"32","author":"MC Milone","year":"2018","unstructured":"Milone MC, O\u2019Doherty U. Clinical use of lentiviral vectors. Leukemia. 2018;32(7):1529\u201341.","journal-title":"Leukemia"},{"issue":"3","key":"3957_CR87","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","volume":"28","author":"H Costa Verdera","year":"2020","unstructured":"Costa Verdera H, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther. 2020;28(3):723\u201346.","journal-title":"Mol Ther"},{"issue":"3","key":"3957_CR88","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-023-00814-5","volume":"25","author":"B Gorovits","year":"2023","unstructured":"Gorovits B, Azadeh M, Buchlis G, Fiscella M, Harrison T, Havert M, et al. Evaluation of cellular immune response to adeno-associated virus-based gene therapy. Aaps j. 2023;25(3): 47.","journal-title":"Aaps j"},{"issue":"1","key":"3957_CR89","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2165\/00063030-200216010-00001","volume":"16","author":"T Ritter","year":"2002","unstructured":"Ritter T, Lehmann M, Volk HD. Improvements in gene therapy: averting the immune response to adenoviral vectors. BioDrugs. 2002;16(1):3\u201310.","journal-title":"BioDrugs"},{"key":"3957_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/v15091801","author":"Y Wang","year":"2023","unstructured":"Wang Y, Shao W. Innate immune response to viral vectors in gene therapy. Viruses. 2023. https:\/\/doi.org\/10.3390\/v15091801.","journal-title":"Viruses"},{"issue":"11","key":"3957_CR91","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31(11):3123\u20136.","journal-title":"Mol Ther"},{"issue":"9","key":"3957_CR92","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/mt.2009.150","volume":"17","author":"VR Arruda","year":"2009","unstructured":"Arruda VR, Favaro P, Finn JD. Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther. 2009;17(9):1492\u2013503.","journal-title":"Mol Ther"},{"issue":"3","key":"3957_CR93","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1056\/NEJMoa2119913","volume":"387","author":"P Chowdary","year":"2022","unstructured":"Chowdary P, Shapiro S, Makris M, Evans G, Boyce S, Talks K, et al. Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med. 2022;387(3):237\u201347.","journal-title":"N Engl J Med"},{"key":"3957_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13: 975803.","journal-title":"Front Immunol"},{"issue":"12","key":"3957_CR95","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/cgt.2015.58","volume":"22","author":"SR Husain","year":"2015","unstructured":"Husain SR, Han J, Au P, Shannon K, Puri RK. Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther. 2015;22(12):554\u201363.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"3957_CR96","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/019262339902700102","volume":"27","author":"AM Pilaro","year":"1999","unstructured":"Pilaro AM, Serabian MA. Preclinical development strategies for novel gene therapeutic products. Toxicol Pathol. 1999;27(1):4\u20137.","journal-title":"Toxicol Pathol"},{"key":"3957_CR97","doi-asserted-by":"publisher","first-page":"1301915","DOI":"10.3389\/fcimb.2023.1301915","volume":"13","author":"F Jiang","year":"2023","unstructured":"Jiang F, Zhang C, Liu W, Liu F, Huang H, Tan Y, et al. Bibliometric analysis of global research trends in adeno-associated virus vector for gene therapy (1991\u20132022). Front Cell Infect Microbiol. 2023;13:1301915.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"3957_CR98","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s11658-023-00507-z","volume":"28","author":"J Lin","year":"2023","unstructured":"Lin J, Jia S, Jiao Z, Chen J, Li W, Cao F, et al. Global research trends in CRISPR-related technologies associated with extracellular vesicles from 2015 to 2022: a bibliometric, dynamic, and visualized study. Cell Mol Biol Lett. 2023;28(1):99.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"3957_CR99","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2435598","volume":"21","author":"Y Qiao","year":"2025","unstructured":"Qiao Y, Xie D, Li Z, Cao S, Zhao D. Global research trends on biomarkers for cancer immunotherapy: visualization and bibliometric analysis. Hum Vaccin Immunother. 2025;21(1): 2435598.","journal-title":"Hum Vaccin Immunother"},{"key":"3957_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/cells11172682","author":"X Wei","year":"2022","unstructured":"Wei X, Pu A, Liu Q, Hou Q, Zhang Y, An X, et al. The bibliometric landscape of gene editing innovation and regulation in the worldwide. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11172682.","journal-title":"Cells"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03957-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03957-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03957-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:28:54Z","timestamp":1762295334000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03957-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3957"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03957-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"556"}}